Skip to content
10-Q

Quarterly Report

UroGen Pharma Ltd. URGN

0001437749-25-015956

← back to feed
Filed
May 12, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 5, 2025 46.11M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $122.11M
Long Term Debt Q1 2025 · Dec 31, 2024 $121.73M
Short Term Investments Q1 2025 · Mar 31, 2025 $112.03M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $104.03M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $171.99M
Current Liabilities Q1 2025 · Mar 31, 2025 $42M
Current Liabilities Q1 2025 · Dec 31, 2024 $45.95M
Total Liabilities Q1 2025 · Mar 31, 2025 $294.08M
Total Liabilities Q1 2025 · Dec 31, 2024 $294.51M
Current Assets Q1 2025 · Mar 31, 2025 $237.18M
Current Assets Q1 2025 · Dec 31, 2024 $276.14M
Total Assets Q1 2025 · Mar 31, 2025 $247.62M
Total Assets Q1 2025 · Dec 31, 2024 $285.71M
Capex Q1 2025 · Mar 31, 2024 $0
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$31.74M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$40.13M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$65.21M
Eps Basic restated Q1 2025 · Mar 31, 2024 −$0.87
Sga Expense Q1 2025 · Mar 31, 2024 $27.3M
Rd Expense Q1 2025 · Mar 31, 2024 $15.49M
Net Income Q1 2025 · Mar 31, 2024 −$32.29M
Operating Income Q1 2025 · Mar 31, 2024 −$25.74M
Gross Profit Q1 2025 · Mar 31, 2024 $17.05M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $1.73M
Revenue Q1 2025 · Mar 31, 2024 $18.78M